Results 71 to 80 of about 14,668 (165)

Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay

open access: yes, 2019
Daratumumab, a monoclonal antibody used to treat relapsed or refractory multiple myeloma, can interfere with protein electrophoresis and immunofixation assays.
Ramanathan, Lakshmi V   +4 more
core   +1 more source

Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies

open access: yes, 2013
Sathish Gopalakrishnan,1 Daryl Tan1,2 1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore Abstract: Although the clinical outcomes of patients
Gopalakrishnan S, Tan D
core  

Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab

open access: yesHaematologica
Daratumumab is an anti-CD38 monoclonal antibody that has shown clinical benefit in both relapsed/refractory as well as newly diagnosed multiple myeloma (MM).
Guido Lancman   +13 more
doaj   +1 more source

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

open access: yesOncoImmunology, 2019
Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of the proposed mechanisms of action is the induction of antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells.
Maria C. Ochoa   +15 more
doaj   +1 more source

B09 | DARATUMUMAB MONOTHERAPY VERSUS ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: "AQUILA" OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION, IMWG 2020 PLUS CYTOGENETIC CRITERIA, AND AGE

open access: yesHaematologica
Introduction. Patients with high-risk smoldering multiple myeloma (SMM) may benefit from early treatment. With SMM risk stratification advancement, post hoc analysis of the AQUILA study using IMWG 2020 (“20/2/20”) and other risk models was conducted to ...
F. Schjesvold   +38 more
doaj   +1 more source

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma:CASSIOPEIA minimal residual disease results [PDF]

open access: yes
Previous results from CASSIOPEIA demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with ...
Rowe, Melissa   +31 more
core   +1 more source

Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma

open access: yesBMC Cancer
Background Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with direct on-tumor and immunomodulatory mechanisms of action. Daratumumab-based treatment is a standard of care for multiple myeloma (MM) based on data from randomized controlled
Luqun Wang   +17 more
doaj   +1 more source

Light Chain Monoclonal Gammopathy of Undetermined Significance: Diagnosis, Biology, and Clinical Management

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1159-1167, November 2026.
ABSTRACT Light chain monoclonal gammopathy of undetermined significance (LC‐MGUS) is defined by an abnormal serum free light chain ratio and elevated involved light chain in the absence of a detectable immunoglobulin heavy chain on immunofixation and of end‐organ damage attributable to a plasma cell disorder.
Sigurður Yngvi Kristinsson   +2 more
wiley   +1 more source

Daratumumab: a game changer in early myeloma

open access: yes
In this issue of Blood, Landgren et al1 report on the efficacy and safety of daratumumab in smoldering multiple myeloma (SMM). Daratumumab was the first anti-CD38 monoclonal antibody to demonstrate efficacy as a single agent in treating patients with ...
González-Calle, Verónica   +1 more
core   +1 more source

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

open access: yesHaematologica, 2015
Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of daratumumab, we explored the possibility of improving daratumumab-mediated ...
Inger S. Nijhof   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy